DRTS — Alpha Tau Medical Ltd.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1871321 ·
Last close
$10.37
Market Cap
$936.68M
52W High
$11.62
52W Low
$6.10
ADV30
776,147
Next earnings
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -13,313,000 -22,939,000 108,773,000 4,636,000 39,421,000
Dec 2025 0 -12,602,000 -12,136,000 105,652,000 12,202,000 28,553,000
Sep 2025 0 -10,730,000 -11,686,000 104,694,000 3,329,000 27,110,000
Jun 2025 0 -9,648,000 -10,114,000 110,954,000 11,703,000 24,331,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-190,136,000
Inventory
Receivables
$336,000
ST Investments
$60,924,000
EBIT TTM
$-42,159,000
Pretax Income TTM
$-42,506,000
Interest Exp TTM
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -42,288,000 -42,627,000 105,652,000 28,553,000 -26,681,000
Dec 2024 0 -36,042,000 -31,750,000 86,204,000 23,538,000 -19,783,000
Dec 2023 0 -35,680,000 -29,157,000 107,388,000 22,913,000 -17,958,000
Dec 2022 0 -32,136,000 -33,762,000 120,149,000 14,492,000 -23,879,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.48

Max Pain — expiry 2026-08-21

max pain strike: $7.50 · spot: $10.37 · call oi: 3,589 · put oi: 563
Expected Move to 2026-08-21: ±$3.17 (30.62%) — implied range $7.19$13.54 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
STVN Stevanato Group S.p.A. $893.28M $17.97
AVR Anteris Technologies Global Corp. $883.87M $9.08
TNDM TANDEM DIABETES CARE INC $996.41M $14.54
INMD InMode Ltd. $839.77M $13.81
BFLY Butterfly Network, Inc. $1.07B $4.54

News headlines (Yahoo Finance, 1h cache)

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-18 20:01 · Yahoo
Alpha Tau to Participate in May Investor Conferences
2026-05-18 12:30 · Yahoo
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
2026-05-11 14:07 · Yahoo
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Obs
2026-05-11 11:00 · Yahoo
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
2026-05-08 13:10 · Yahoo
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
2026-05-08 13:00 · Yahoo
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute
2026-05-07 13:00 · Yahoo
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrol
2026-05-05 13:14 · Yahoo
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
2026-05-04 13:17 · Yahoo
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
2026-04-27 13:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.